AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
25 Sep 2020 07:00 AM
RNS
Directorate Change
21 Sep 2020 07:05 AM
RNS
Lynparza EU recommendation in prostate cancer
21 Sep 2020 07:00 AM
RNS
Lynparza EU recommendation in ovarian cancer
21 Sep 2020 07:00 AM
RNS
Tagrisso reduced early lung cancer brain recurrenc
10 Sep 2020 07:01 AM
RNS
AstraZeneca to list all US securities on Nasdaq
10 Sep 2020 07:00 AM
RNS
Fasenra PhIII OSTRO trial met co-primary endpoints
01 Sep 2020 03:00 PM
RNS
Total Voting Rights
01 Sep 2020 07:00 AM
RNS
Imfinzi approved in EU for small cell lung cancer
01 Sep 2020 07:00 AM
RNS
Farxiga reduces CKD progression and risk of death
25 Aug 2020 07:00 AM
RNS
Ph I trial begins for COVID-19 monoclonal antibody
21 Aug 2020 07:00 AM
RNS
Imfinzi approved in Japan for SCLC
18 Aug 2020 07:00 AM
RNS
Imfinzi US Priority Review; four-week, fixed dose
04 Aug 2020 07:00 AM
RNS
AstraZeneca prices a $3bn bond issue
03 Aug 2020 03:00 PM
RNS
Total Voting Rights
30 Jul 2020 07:25 AM
RNS
Tagrisso US BTD for EGFRm adjuvant lung cancer
30 Jul 2020 07:18 AM
RNS
AZN: H1 2020 results
29 Jul 2020 07:00 AM
RNS
Board Committee Changes
28 Jul 2020 07:00 AM
RNS
Farxiga DAPA-CKD trial met all endpoints
27 Jul 2020 07:10 AM
RNS
Calquence receives positive CHMP opinion for CLL
27 Jul 2020 07:05 AM
RNS
Imfinzi recommended for EU approval in SCLC
27 Jul 2020 07:00 AM
RNS
AstraZeneca enters collaboration in oncology
24 Jul 2020 07:00 AM
RNS
Breztri Aerosphere approved in the US for COPD
22 Jul 2020 03:00 PM
RNS
Holding(s) in Company
22 Jul 2020 03:00 PM
RNS
Holding(s) in Company
21 Jul 2020 03:00 PM
RNS
Holding(s) in Company
21 Jul 2020 03:00 PM
RNS
Holding(s) in Company
20 Jul 2020 02:41 PM
RNS
COVID-19 vaccine Phase I/II showed immune response
16 Jul 2020 07:00 AM
RNS
Director Declaration
09 Jul 2020 07:00 AM
RNS
Brilinta granted US FDA Priority Review for stroke
08 Jul 2020 07:00 AM
RNS
Lynparza approved in the EU for pancreatic cancer
01 Jul 2020 03:00 PM
RNS
Total Voting Rights
30 Jun 2020 03:00 PM
RNS
Director/PDMR Shareholding
30 Jun 2020 07:00 AM
RNS
Selumetinib granted Japan orphan drug designation
17 Jun 2020 03:03 PM
RNS
Holding(s) in Company
17 Jun 2020 03:00 PM
RNS
Holding(s) in Company
15 Jun 2020 07:00 AM
RNS
Agreement to Supply Europe with COVID-19 Vaccine
11 Jun 2020 07:00 AM
RNS
EMTN Programme Routine Technical Update
01 Jun 2020 03:00 PM
RNS
Total Voting Rights
01 Jun 2020 03:00 PM
RNS
Block listing Interim Review
01 Jun 2020 07:00 AM
RNS
Lynparza EU CHMP opinion in pancreatic cancer
01 Jun 2020 07:00 AM
RNS
Brilinta obtains additional US approval
29 May 2020 04:41 PM
RNS
Second Price Monitoring Extn
29 May 2020 04:35 PM
RNS
Price Monitoring Extension
29 May 2020 01:00 PM
RNS
Enhertu DESTINY-Gastric01 results from ASCO 2020
29 May 2020 01:00 PM
RNS
Imfinzi sustained overall survival in CASPIAN
29 May 2020 07:00 AM
RNS
Tagrisso unprecedented adjuvant lung cancer data
26 May 2020 10:30 AM
RNS
Director/PDMR Shareholding
22 May 2020 07:00 AM
RNS
Enhertu US orphan designation in gastric cancer
21 May 2020 07:00 AM
RNS
AstraZeneca advances response to COVID-19 outbreak
20 May 2020 07:00 AM
RNS
Lynparza approved in the US for prostate cancer

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings